Next-Generation Nonviral Vectors for mRNA Vaccine Delivery
Next-Generation Nonviral Vectors for mRNA Vaccine Delivery
复制标题
DOI：
10.1002/macp.202100443
复制
发表时间：
2022-01-24
影响因子：
2.5
通讯作者：
Liu, Shiyong
中科院分区：
文献类型：
--
作者：
Chen, Minglong;Hu, Xianglong;Liu, Shiyong
接种疫苗是保护个人免受严重疾病和疫苗可预防疾病并发症影响的最有希望的方法之一。目前，已建立了多个信使核糖核酸治疗管道，用于预防和治疗包括传染病、心脏病、纤维化等在内的各种疾病；值得注意的是，BNT162b2和信使核糖核酸-1273现已用于临床治疗冠状病毒病2019年(新冠肺炎)，这标志着信使核糖核酸应用取得了前所未有的发展。然而，基因疫苗存在着转染率低、副作用大、降解快等缺点，严重限制了其临床应用。因此，需要进一步的深入研究来优化递送系统，以提高mRNA疫苗的安全性、有效性和稳定性。从这一角度出发，总结和提出了信使核糖核酸靶向传递生物材料的设计原则，并对信使核糖核酸疫苗的发展趋势和机遇进行了展望。
Vaccination is one of the most promising approaches to protect individuals from serious illness and complications of vaccine-preventable diseases. Currently, several mRNA therapeutic pipelines have been established to prevent and treat various diseases, including infectious diseases, heart disease, fibrosis, etc.; note that BNT162b2 and mRNA-1273 are now in clinical application against coronavirus disease 2019 (COVID-19), which marks an unprecedented development for mRNA application. However, some drawbacks of mRNA vaccination such as restricted transfection efficiency, potential adverse effects, and fast degradation severely limit their clinical application. Therefore, additional in-depth research is required to optimize the delivery systems for the improvement of safety, effectiveness, and stability of mRNA vaccines. In this perspective, the design principles of biomaterials for mRNA targeted delivery are summarized and proposed, and an outlook for the tendency and opportunities of mRNA vaccines is given.